Scarica l'app Stockscreener
7.35
3.80%
-0.29
Dopo l'orario di chiusura:
7.54
0.19
+2.59%
Precedente Chiudi:
$7.64
Aprire:
$7.51
Volume 24 ore:
854.42K
Relative Volume:
0.88
Capitalizzazione di mercato:
$454.55M
Reddito:
-
Utile/perdita netta:
$-156.40M
Rapporto P/E:
-2.2409
EPS:
-3.2799
Flusso di cassa netto:
$-151.53M
1 W Prestazione:
-11.98%
1M Prestazione:
-6.84%
6M Prestazione:
-20.37%
1 anno Prestazione:
+82.84%
Intervallo 1D:
$7.34
$7.53
Intervallo di 1 settimana:
$7.34
$8.38
Portata 52W:
$3.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
7.35 | 472.48M | 0 | -156.40M | -151.53M | -3.2799 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-05-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
| 2024-07-03 | Iniziato | H.C. Wainwright | Neutral |
| 2024-03-04 | Iniziato | JP Morgan | Overweight |
| 2024-03-04 | Iniziato | Leerink Partners | Outperform |
| 2024-03-04 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-04 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna at wells fargo healthcare conference: autoimmune car t push advances - Investing.com Canada
KYTX: Miv-cel shows unprecedented efficacy in SPS, with regulatory and commercial milestones set for 2027 - TradingView
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
BlackRock Inc. Purchases Shares of 3,134,807 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Wells Fargo Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX) - The Globe and Mail
Kyverna Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts - BioPharma Dive
Kyverna (KYTX): Posts a 3.09% Loss to $8.16 at the Close; Chart Watch: the Session Ends Within the Reported Technical Boundaries in the Latest SessionResistance Breakout Stocks - vinanet.vn
Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.3%Time to Sell? - MarketBeat
Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®
Kyverna (KYTX) Latest Reading: Declines 5.03% to $8.50 in the Latest Session; Session Range View: the Session Ends Within the Reported Technical Boundaries in the Available RecordDay Trade Opportunities - vinanet.vn
Kyverna Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% HigherShould You Buy? - MarketBeat
AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
KYTX Edges Higher: Kyverna Therapeutics Climbs 1.11% to $8.17Fibonacci Retracement - Vinanet
Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst - MarketBeat
Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KYTX Q1 2026 Earnings: Narrower-than-Expected Loss of -0.66 per Share Highlights Clinical-Stage Cost Discipline - vinanet.vn
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha
Kyverna Therapeutics advances autoimmune drug m... - pluang.com
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Kyverna Therapeutics (KYTX) Earnings Date and Reports 2026 $KYTX - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Kyverna Therapeutics narrows Q2 losses, secures RMAT for miv-cel - scanx.trade
Kyverna Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kyverna Therapeutics Announces Q2 2026 Financial Results and Operational Update - Kalkine Media
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results - The Manila Times
KYTX: Q2 2026 net loss narrowed to $38.3M as miv-cel advanced toward commercialization - TradingView
Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan
Renaissance Technologies LLC Grows Stock Holdings in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Kyverna Therapeutics, Inc. expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kyverna Therapeutics (KYTX) Gains 1.44% to $7.75, Holding Above Key SupportDay Trade Opportunities - vinanet.vn
Kyverna Therapeutics and ElevateBio Sign Commercial Manufacturing Agreement for Miv-Cel - BioPharm International
Kyverna Therapeutics (KYTX) Expected to Post Quarterly Earnings on Tuesday - MarketBeat
BlackRock (NYSE: BLK) discloses 5.1% beneficial stake in Kyverna Therapeutics (KYTX) - Stock Titan
ElevateBio inks deal to supply Kyverna’s CAR T-cell therapy for gMG - Myasthenia Gravis News
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel - BioInformant
Kyverna Therapeutics Inc (KYTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kyverna and ElevateBio collaborate on miv-cel - The Pharma Letter
William Blair Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating - Moomoo
Kyverna, ElevateBio Ink Manufacturing Agreement for Miv-Cel Supply - Contract Pharma
KYTX|Kyverna Therapeutics Inc|Price:7.890|Chg%:+0.480 - TradingKey
Kyverna Therapeutics, Inc. and Elevatebio, Inc. Enter into Commercial Manufacturing and Supply Agreement for Miv-Cel - marketscreener.com
Kyverna, ElevateBio sign manufacturing pact for miv-cel supply - Investing.com
Kyverna Therapeutics and ElevateBio Secure Scalable Manufacturing Agreement to Launch First CAR T-Cell Therapy for Autoimmune Diseases - Minichart
Kyverna Therapeutics Inc (KYTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kyverna Therapeutics Inc (KYTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):